0001628280-26-029812
SEC filingMedifast reported Q1 2026 revenue of $76.0 million, down 34.3% year-over-year, with net loss of $2.1 million and issued full-year revenue guidance of $270-$300 million.
Medifast's Q1 2026 results reflect ongoing challenges in its coach network amid a tough operating environment, particularly from GLP-1 medication adoption impacting client acquisition. Active earning coaches dropped 44.9% to 14,000, driving a 34.3% revenue decline to $76.0 million, though revenue per coach surged 19.2% to $5,432 due to prioritization of productive coaches and network efficiencies. Gross profit fell 38.6% to $51.8 million, with margins contracting 470 basis points to 68.1% from lost fixed cost leverage. SG&A declined 35.6% to $55.1 million (72.4% of revenue), aided by lower coach compensation, reduced marketing, and a $2.2 million one-time gain from selling the Maryland Distribution Center, though fixed cost deleveraging offset some benefits. Operating loss widened to $3.3 million (4.3% of revenue) from $1.3 million last year. CEO Dan Chard highlighted progress in coach productivity, leadership advancement, and field engagement as leading indicators for future growth, supported by the company's metabolic health strategy. Balance sheet strength persists with $168.9 million in cash/investments and no debt. Guidance signals further pressure with Q2 revenue at $60-80 million and full-year at $270-300 million, expecting continued coach declines but positioning for long-term recovery.